34,500 Shares in PROCEPT BioRobotics Corporation $PRCT Acquired by Militia Capital Management LLC

Militia Capital Management LLC acquired a new position in shares of PROCEPT BioRobotics Corporation (NASDAQ:PRCT) during the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 34,500 shares of the company’s stock, valued at approximately $863,000. Militia Capital Management LLC owned approximately 0.06% of PROCEPT BioRobotics as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently bought and sold shares of the company. AQR Capital Management LLC increased its stake in shares of PROCEPT BioRobotics by 7.3% in the 1st quarter. AQR Capital Management LLC now owns 18,892 shares of the company’s stock valued at $1,101,000 after buying an additional 1,286 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its stake in shares of PROCEPT BioRobotics by 9.9% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 153,158 shares of the company’s stock valued at $8,923,000 after acquiring an additional 13,767 shares during the period. Intech Investment Management LLC lifted its stake in shares of PROCEPT BioRobotics by 54.4% during the first quarter. Intech Investment Management LLC now owns 28,389 shares of the company’s stock valued at $1,654,000 after acquiring an additional 10,002 shares during the period. Prudential Financial Inc. boosted its holdings in PROCEPT BioRobotics by 100.4% in the second quarter. Prudential Financial Inc. now owns 6,815 shares of the company’s stock valued at $393,000 after acquiring an additional 3,415 shares during the last quarter. Finally, State Street Corp boosted its holdings in PROCEPT BioRobotics by 6.9% in the second quarter. State Street Corp now owns 1,269,110 shares of the company’s stock valued at $73,101,000 after acquiring an additional 81,849 shares during the last quarter. 89.46% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on PRCT shares. Piper Sandler reiterated an “overweight” rating and issued a $35.00 price objective (up from $28.00) on shares of PROCEPT BioRobotics in a research report on Thursday, April 30th. Citigroup downgraded shares of PROCEPT BioRobotics to a “hold” rating in a research report on Thursday, July 2nd. Leerink Partners cut shares of PROCEPT BioRobotics from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $31.00 to $29.00 in a research note on Thursday, June 11th. Wall Street Zen upgraded shares of PROCEPT BioRobotics from a “strong sell” rating to a “sell” rating in a research report on Saturday, April 25th. Finally, UBS Group downgraded PROCEPT BioRobotics from a “buy” rating to a “neutral” rating and set a $20.00 price objective for the company. in a report on Tuesday, July 28th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, PROCEPT BioRobotics presently has a consensus rating of “Hold” and a consensus price target of $33.45.

PROCEPT BioRobotics Price Performance

Shares of NASDAQ PRCT opened at $18.62 on Monday. PROCEPT BioRobotics Corporation has a 52-week low of $16.67 and a 52-week high of $51.38. The company has a debt-to-equity ratio of 0.15, a quick ratio of 5.51 and a current ratio of 6.73. The stock has a market cap of $1.06 billion, a P/E ratio of -10.23 and a beta of 0.89. The firm has a 50 day moving average price of $22.39 and a 200 day moving average price of $25.15.

PROCEPT BioRobotics News Summary

Here are the key news stories impacting PROCEPT BioRobotics this week:

• Neutral Sentiment: Investors who purchased PROCEPT shares between February 28, 2024, and February 25, 2026, have until September 22, 2026, to seek appointment as lead plaintiff in the pending class action. The notices are procedural and do not represent a court finding of wrongdoing. Deadline Alert: Procept BioRobotics Corporation Shareholders
• Negative Sentiment: The core allegations involve repeated underperformance in unit and handpiece sales, late-quarter bulk discounts, excess customer inventory, and sales being pulled forward. Plaintiffs allege these practices may have inflated recurring-revenue metrics and that the risks were not adequately disclosed. PROCEPT Faces Securities Class Action Amid Sales Pull-In Concerns
• Negative Sentiment: The unusually high volume of nearly identical law-firm announcements increases the visibility of the litigation and could weigh on the stock through potential legal costs, reputational damage, and uncertainty regarding the sustainability of demand and future revenue growth. PROCEPT Securities Fraud Class Action and Inventory Issues
• Negative Sentiment: UBS reportedly lowered its rating on PRCT to “Neutral,” adding to the cautious backdrop surrounding the company and its sales outlook. PROCEPT Rating Lowered to Neutral at UBS

PROCEPT BioRobotics Company Profile

PROCEPT BioRobotics, Inc is a medical device company specializing in the development and commercialization of robotic systems for the treatment of benign prostatic hyperplasia (BPH). The company’s technology leverages precision robotics and real-time imaging to perform minimally invasive procedures, aiming to reduce patient recovery time and improve clinical outcomes compared to traditional surgical approaches.

The company’s flagship product, the AquaBeam Robotic System, uses a high-velocity waterjet to selectively remove prostate tissue while preserving surrounding healthy structures.